Mission: To help our clients realize their most important goals. And beyond.


Peer-reviewed articles / reviews:


  • Lyman M., Lieuw V., Richardson R., Timmer A., Stewart C., Granger S., Woods R., Silacci M., Grabulovski D. and Newman R. (2018) A bispecific antibody that targets IL-6 receptor and IL-17A for the potential treatment of patients with autoimmune and inflammatory diseases. J Biol Chem, doi: 10.1074/jbc.M117.818559.


  • Silacci M., Lembke W., Woods R., Attinger-Toller I., Baenziger-Tobler N., Batey S., Santimaria R., von der Bey U., Koenig-Friedrich S., Zha W., Schlereth B., Locher M., Bertschinger J., and Grabulovski D. (2016) Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs, 8(1), pp. 141-149



  • Wuellner U., Klupsch K., Buller F., Attinger-Toller I., Santimaria R., Zbinden I., Henne P., Grabulovski D., Bertschinger J., and Brack S. (2015) Bispecific CD3/HER2 targeting FynomAb induces redirected T cell-mediated cytolysis with high potency and enhanced tumor selectivity. Antibodies, 4, pp. 426-440

  • Wuellner U. and Grabulovski D. (2015) Alternative Scaffolds as Therapeutics in Cancer and Other Diseases. For Immunopathol Dis Therap, DOI: 10.1615/ForumImmunDisTher.2015014027



  • Brack S., Attinger-Toller I., Schade B., Mourlane F., Klupsch K., Woods R., Hachemi H., von der Bey U., Koenig-Friedrich S., Bertschinger J., and Grabulovski D. (2014) A Bispecific HER2 Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action. Mol Cancer Ther, 13, 2030-2039.


  • Silacci M., Baenziger-Tobler N., Lembke W., Zha W., Batey S., Bertschinger J., and Grabulovski D. (2014) Linker Length Matters, Fynomer-Fc fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency. J Biol Chem, 289, 14392-14398.



  • Banner D.W., Gsell B., Benz J., Bertschinger J., Burger D., Brack S., Cuppuleri S., Debulpaep M., Gast A., Grabulovski D., Hennig M., Hilpert H., Huber W., Kuglstatter A., Kusznir E., Laeremans T., Matile H., Miscenic C., Rufer A.C., Schlatter D., Steyaert J., Stihle M., Thoma R., Weber M., Ruf A. (2013) Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr D Biol Crystallogr, 69 (Pt 6), pp. 1124-1137.



  • Schlatter D., Brack S., Banner D., Batey S., Benz J., Bertschinger J., Huber W., Joseph C., Rudolph M., Rufer A., van der Klooster A., Weber M., Grabulovski D. and Hennig M. (2012) Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. MAbs, (4):4, 497-508.


  • Bertschinger, J.*, Grabulovski, D.* and Neri, D. (2007) Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel, 20, 57-68.

*these authors contributed equally to the work


  • Grabulovski, D., Kaspar, M. and Neri, D. (2007) A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties. J Biol Chem, 282, 3196-3204.



  • Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L. and Neri, D. (2005) Engineered vascular-targeting antibody-interferon- gamma fusion protein for cancer therapy. Int J Cancer, 116, 304-313

Book chapters:

  • Grabulovski D. and Bertschinger J. (2012) Scaffolds: small globular proteins as antibody substitutes; invited book chapter in DRUG DISCOVERY AND DEVELOPMENT: TECHNOLOGY IN TRANSITION, ed. Prof. Raymond G. Hill, Elsevier


  • Grabulovski, D. and Neri, D. (2007) Vascular tumor targeting, in TUMOR ANGIOGENESIS, invited book chapter, ed. Marme D & Fusenig N, Springer Verlag 

Patent applications / patents:

  • WO2015141862: Antibody-Fynomer conjugates
  • WO2014170063: Novel bispecific binding molecules with antitumoral activity
  • WO2014106583: Human serum albumin binding compounds and fusion proteins thereof
  • WO2014044758: Novel IL-17A binding molecules and medical uses thereof
  • WO2013135588: Novel binding molecules with antitumoral activity
  • EP2597102: A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17
  • WO2012159836: New chymase binding compounds and medical uses thereof
  • WO2011023685: IL-17 binding compounds and medical uses thereof
  • WO2008022759: Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase